CD22+ Relapsed/Refractory B-ALL
1 clinical trials · Condition
◉ Watch CD22+ Relapsed/Refractory B-ALL
| Record | Firm | Date |
|---|---|---|
| Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL (NCT02844530) | Nantes University Hospital |
Track CD22+ Relapsed/Refractory B-ALL automatically
Every clearance here is in the API, with alerts when new ones post.